Amgen has been honoured with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for NplateÂ® (romiplostim).
A ceremony held in London by Scrip awarded Amgen with the Best Overall Pipeline award. This was in recognition of the size, quality, novelty and market potential of the company’s pipeline, as well as its mix of candidates across development stages.
According to the judges, Amgen’s pipeline is notable for its focus on unmet clinical need.
“We are very pleased to be honored by our industry peers with these two awards,” said Dr Roger M Perlmutter, Executive Vice President of Research and Development at Amgen. “Over the past decade, we have worked very hard to develop a robust pipeline that focuses on novel therapeutics to treat serious illnesses.”
With more than 50 molecules in development, the majority of which target pathways that have not previously been addressed in humans, Amgen’s pipeline includes potential new treatments for various cancers, asthma, diabetes, cardiovascular disease and many other life-threatening conditions.
One of the most promising candidates in Amgen’s pipeline, denosumab, is an in-house discovery that reflects a novel approach to treating bone loss and destruction.
Amgen has filed for regulatory approval of denosumab in postmenopausal osteoporosis (PMO) and bone loss due to hormone ablation in breast and prostate cancer patients in the United States (US), Europe, Switzerland, Canada and Australia.